Baystate Wealth Management’s Vaxcyte PCVX Stock Holding History

Baystate Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$2.51K	Buy	+40	New	+$2.08K	﹤0.01%	1020

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baystate Wealth Management's PCVX Position: Q4 2023 in Review

Baystate Wealth Management opened a new position in Vaxcyte (PCVX) in Q4 2023: 40 shares worth $2.51K. The stake represents ﹤0.01% of the portfolio and ranks #1020 among its holdings.

223 funds tracked by Wall St. Rank hold PCVX as of Q4 2023.

Baystate Wealth Management held 40 shares of Vaxcyte worth $2.51K as of Q4 2023.
Vaxcyte was a new Baystate Wealth Management position in Q4 2023.
Vaxcyte made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1020 holding.
223 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.